Pacira BioSciences Inc
Research Pacira BioSciences Inc (PCRX) on Bullrun: valuation model: 43.8% overvalued, market cap USD 1.02B, P/E 73.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPCRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal43.8% overvalued
- Market capUSD 1.02B
- P/E73.6
- Financial periodQ2 2026
- RevenueUSD 192.40M
- Net incomeUSD 4.65M
- Free cash flowUSD 56.12M
- Gross margin77.0%
Valuation Snapshot
Bullrun's latest valuation model marks Pacira BioSciences Inc as 43.8% overvalued; latest market cap is USD 1.02B; P/E is 73.6.
Peer valuation comparison
Latest P/E is 73.55x versus a Healthcare sector median of 24.46x (200.7% above).
Latest P/E is 73.55x versus a United States median of 24.87x (195.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 726.41M | USD 7.00M | USD 136.66M | 79.4% | 0.16 | USD 158.55M | USD 372.19M | USD 693.11M |
| FY2024 | USD 700.97M | -USD 99.60M | USD 178.75M | 75.7% | -2.15 | USD 276.77M | USD 585.32M | USD 778.35M |
| FY2023 | USD 674.98M | USD 42.00M | USD 139.49M | 72.6% | 0.89 | USD 153.30M | USD 522.44M | USD 870.13M |
| FY2022 | USD 666.82M | USD 15.90M | USD 115.20M | 70.1% | 0.34 | USD 104.14M | USD 689.47M | USD 775.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.02B | 73.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.06B | 161.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 871.17M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.57B | 421.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.77B | 96.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.69B | 65.4 | n/a | n/a |
About Pacira BioSciences Inc
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Pacira BioSciences Inc overvalued or undervalued?
Bullrun's valuation model currently marks Pacira BioSciences Inc as 43.8% overvalued.
What is Pacira BioSciences Inc's market cap?
Pacira BioSciences Inc's market capitalization is USD 1.02B.
What is Pacira BioSciences Inc's P/E ratio?
Pacira BioSciences Inc's price-to-earnings (P/E) ratio is 73.6.
What does Pacira BioSciences Inc do?
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.